UFTによる口腔領域扁平上皮癌患者の1次治療後長期維持化学療法の検討

概要

論文の詳細を見る
The effectiveness and safety of UFT as adjuvant chemotherapy were examined in comparison with historical control group in which any kind of adjuvant chemotherapy was not carried. UFT therapy was carried out in 25 oral cancer patiets after primary treatment. UFT was administered orally at a daily dose of 300mg. The average period was 575. 3 days and average dose was 185. 2g.<BR>The 3-year survival rate was 94.4% in the UFT group and 82.6% in the control group. The 3-year disease-free rate was 88.0% in the UFT group and 68.0% in the control group. When the object of analysis was restricted to stage II-IV, the 3-year disease-free rate was 90.5% in the UFT group and 61.9% in the control group (p<0.05, Cox-Mantel test).<BR>Side effects were observed in 9 cases (36.0%), mainly digestive tract symptoms, liver dysfunction and bone marrow suppression. These were generally mild and only in 2 cases was administration of UFT stopped due to side effects.<BR>It is suggested that UFT may be administered to oral cancer patients usefully and safely. However, a further randomized controlled study is necessary to confirm these findings.